Cardea Bio, a pioneering company in the graphene biosensor market, has been acquired by Paragraf, a leading integrated device manufacturer. This acquisition aims to accelerate the mass production of a new generation of devices that provide real-time analysis in point-of-need tests for the agritech, healthcare, and environmental monitoring sectors.
Cardea Bio introduces a groundbreaking paradigm in the integration of electronics and biology through their Biological Processing Unit (BPU). The BPU platform, consisting of graphene-based biology-gated field-effect transistors, enables the seamless integration of biological material with electronics, revolutionizing the way we understand and utilize these technologies.
Generated from the website